Status:
COMPLETED
A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8
Lead Sponsor:
AstraZeneca
Conditions:
Hyperkalemia
Eligibility:
All Genders
18-130 years
Phase:
PHASE2
Brief Summary
The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patient...
Eligibility Criteria
Inclusion
- ≥ 18 years of age
- Potassium ≥5.8 mmol/L
Exclusion
- Possible pseudohyperkalaemia
- Hyperkalaemia caused by any condition for which a therapy directed against the underlying cause of hyperkalaemia would be a better treatment option than treatment with insulin and glucose.
- Dialysis session expected within 4h after randomization
- Treated with any therapy intended to lower S-K between arriving at the hospital and randomization during Visit 1.
Key Trial Info
Start Date :
February 13 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 21 2018
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT03337477
Start Date
February 13 2018
End Date
December 21 2018
Last Update
January 28 2020
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Montgomery, Alabama, United States, 36106
2
Research Site
Phoenix, Arizona, United States, 85008
3
Research Site
Detroit, Michigan, United States, 48201
4
Research Site
Detroit, Michigan, United States, 48202